FIELD: medicine.
SUBSTANCE: method of prevention and method of treatment of gastrointestinal diseases in animals or people, such as diarrhea, antibiotics-associated diarrhea, inflammatory intestinal disease and diarrhea, caused by Clostridium difficile (CDAD), includes stage of introduction of efficient amount of strain of Bacillus subtilus ATCC PTA-6737, as probiotic. Strain produces lipopeptide sufractine and represents medication for treatment of gastrointestinal diseases in animals or people, such as diarrhea, antibiotics-associated diarrhea, inflammatory intestinal disease and diarrhea, caused by Clostridium difficile (CDAD).
EFFECT: invention ensures high efficiency in treatment and prevention of gastrointestinal diseases in people or animals.
15 cl, 14 dwg, 12 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS FOR TREATING CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES | 2011 |
|
RU2575477C2 |
| 5-HYDROXYMETHYLOXAZOLIN-2-ONE DERIVATIVES FOR TREATING BACTERIAL INTESTINAL DISEASES | 2009 |
|
RU2527769C2 |
| ANTIBACTERIAL COMPOUNDS | 2009 |
|
RU2525915C2 |
| ANIONIC POLYMERS BEING THE SUBSTANCES FOR BINDING TOXINS AND ANTIBACTERIAL SUBSTANCES | 2000 |
|
RU2246938C2 |
| COMPOSITION AND METHOD OF TREATING AND PREVENTING INTESTINAL INFECTION AND INFLAMMATION | 2016 |
|
RU2738803C2 |
| USE OF MICROBIAL COMMUNITIES FOR THE TREATMENT OF HUMANS AND ANIMALS | 2017 |
|
RU2758387C2 |
| ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
| USE OF MICROBIAL COMMUNITIES FOR TREATING HUMANS AND ANIMALS | 2017 |
|
RU2823233C2 |
| METHOD FOR TREATMENT OF HUMAN DISEASES CAUSED BY GRAM-POSITIVE BACTERIA | 2017 |
|
RU2661613C1 |
| AGENT FOR PROPHYLAXIS AND/OR TREATMENT OF UNDESIRED INFLAMMATION ACTIVITY AND CANCER PROPHYLAXIS | 2000 |
|
RU2279282C2 |
